頁籤選單縮合
| 題 名 | 慢性C型肝炎之健保給付新藥探討=The New Therapeutic Drugs of Health Insurance Payment for Chronic Hepatitis C Virus |
|---|---|
| 作 者 | 洪瑄佑; 林慧娟; | 書刊名 | 藥學雜誌 |
| 卷 期 | 35:2=139 2019.06[民108.06] |
| 頁 次 | 頁2-10 |
| 分類號 | 418.285 |
| 關鍵詞 | 直接作用抗病毒藥物; C型肝炎; Direct-acting antiviral agent; DAA; HCV; |
| 語 文 | 中文(Chinese) |
| 中文摘要 | 早期台灣治療慢性C型肝炎,健保給付治療藥物有干擾素 (Interferon) 與抗病 毒藥物 (Ribavirin) 但有禁忌症及嚴重副作用,自2011年起,美國食品及藥物管理 局 (Food and drug administration, FDA) 陸續核准新治療藥物機轉-直接抗病毒 (directacting antiviral, DAA),為口服劑型增加病患服藥順從性,其治癒率可達9成以上,但 早期台灣無健保給付,需採自費治療,價格昂貴,且需專案申請進口。自2017年1月 開始,衛生福利部中央健康保險署陸續開放給付七個新型 DAA 藥品,為 Daklinza、 Sunvepra、Viekirax、Exviera、Zepatier、Harvoni、Sovaldi,分別針對C肝病毒 genotype 1a,1b、genotype 1a,1b、genotype 1a,1b,4、genotype 1a,1b、genotype 1a,1b,4、 genotype 1,4,5,6、genotype 1,2,3,4,本文將探討這七個健保給付新藥。 |
| 英文摘要 | Early treatment of chronic hepatitis C in Taiwan, the therapeutic drugs of health insurance payment only Interferon and Ribavirin, but there had contraindications and serious side effects. Since 2011, Food and Drug Administration (FDA) approved the new therapeutic drug:direct-acting antiviral (DAA), which increased the patient's compliance with oral medication, even achieved over 90% cure rate. However, it so expensive and needed pays own expenses, therefore be apply in advance for import license. Since January 2017, National Health Insurance Administration MOHW appoved the DAA medicines: Daklinza, Sunvepra, Viekirax, Exviera, Zepatier, Harvoni and Sovaldi. Major genotypes of the HCV focused on genotype 1a,1b、genotype 1a,1b、genotype 1a,1b,4、genotype 1a,1b、genotype 1a,1b,4、genotype 1,4,5,6、genotype 1,2,3,4. |
本系統中英文摘要資訊取自各篇刊載內容。